Your browser doesn't support javascript.
loading
Major response to temozolomide as first-line treatment for newly-diagnosed DDR2-mutated glioblastoma: A case report.
El Husseini, K; Marguet, F; Lamy, A; Magne, N; Fontanilles, M.
Affiliation
  • El Husseini K; Department of Medical Oncology, Cancer Centre Henri-Becquerel, rue d'Amiens, 76000, Rouen, France.
  • Marguet F; Normandie Univ, Uni Rouen, Inserm U1245, Normandy Centre for Genomic and Personalized Medicine, Department of Pathology, Rouen University Hospital, 76031, Rouen, France.
  • Lamy A; Department of Pathology, Rouen University Hospital, 76031, Rouen, France.
  • Magne N; Department of Pathology, Rouen University Hospital, 76031, Rouen, France.
  • Fontanilles M; Department of Medical Oncology, Cancer Centre Henri-Becquerel, rue d'Amiens, 76000, Rouen, France; Normandie Univ, UNIROUEN, Inserm U1245, IRON group, Normandy Centre for Genomic and Personalized Medicine, Rouen University Hospital, 76031, Rouen, France. Electronic address: maxime.fontanilles@chb.un
Rev Neurol (Paris) ; 176(5): 402-404, 2020 05.
Article in En | MEDLINE | ID: mdl-32139182
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Glioblastoma Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Rev Neurol (Paris) Year: 2020 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Glioblastoma Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Rev Neurol (Paris) Year: 2020 Document type: Article